BAYER AG Products & Brands - Key Offerings and Insights

Products

Category

Product

Brand

Description

Prevention and Treatment of Prostate Cancer (PHM113C)

Androgen receptor inhibitor/antiandrogen	Nubeqa	Sales of the Nubeqa (darolutamide) in 2022 were nearly twice those of 2021, with significant gains in all regions. Bayer’s U.S. patent on active ingredient expires in 2030.
Targeted radioligand therapies	Xofigo	Xofigo (radium Ra223 dichloride) patent on use expired in the U.S. in 2022 and will expire in key European markets in 2024.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.